Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 16Non-Muscle Invasive Bladder Neoplasms 11Stomach Neoplasms 7Carcinoma, Hepatocellular 6Neoplasm Metastasis 5Liver Neoplasms 5Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Anus Neoplasms 4Pancreatic Neoplasms 3Appendiceal Neoplasms 3Anal Canal Carcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Peritoneal Neoplasms 2Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Neoplasm 1Sarcoma 1Rectal Neoplasms 1

Interventions

veliparib 1tipifarnib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Neoplasm × Mitomycin × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡